Precigen Aktie

4,81 EUR +0,13 EUR +2,78 %

24.06.2026

BMN

5,38 USD +0,03 USD +0,47 %

24.06.2026

BTT

Precigen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.1,68 Mrd. EUR

Div. Rendite0,00%

WKNA2PZG1

ISINUS74017N1054

SymbolPGEN

Precigen Aktien News

Sortieren:Datum Meistgelesen

12.06.26MotleyFoolIs Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?

01.06.26ZacksPrecigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?

13.05.26BenzingaTranscript: Precigen Q1 2026 Earnings Conference Call

WerbungPrecigen-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

13.05.26ZacksPrecigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates

13.05.26MotleyFoolPrecigen (PGEN) Q1 2026 Earnings Transcript

26.03.26BenzingaThese Analysts Boost Their Forecasts On Precigen Following Q4 Results

26.03.26BenzingaOlaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday

25.03.26ZacksPrecigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates

25.03.26MotleyFoolPrecigen (PGEN) Q4 2025 Earnings Call Transcript

12.01.26PR NewswirePrecigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference

05.01.26PR NewswirePrecigen to Present at the 44th Annual J.P. Morgan Healthcare Conference

02.12.25MotleyFoolPrecigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet?

13.11.25MotleyFoolPrecigen (PGEN) Q3 2025 Earnings Call Transcript

13.11.25PR NewswirePrecigen Reports Third Quarter 2025 Financial Results and Business Updates

06.11.25PR NewswirePrecigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

01.11.25MotleyFoolPatient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares

13.10.25PR NewswirePrecigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Res...

03.09.25PR NewswirePrecigen Announces Up to $125 Million Non-Dilutive Financing

25.08.25PR NewswirePrecigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

15.08.25BenzingaEvolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday

15.08.25BenzingaWhy Is Precigen Stock Surging On Friday?

15.08.25PR NewswirePrecigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

14.05.25PR NewswirePrecigen Reports First Quarter 2025 Financial Results and Business Updates

16.04.25PR NewswirePrecigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

19.03.25PR NewswirePrecigen Reports Full Year 2024 Financial Results and Business Updates

13.03.25PR NewswirePrecigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

25.02.25PR NewswireFDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

13.01.25PR NewswirePrecigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

09.01.25PR NewswirePrecigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

30.12.24PR NewswirePrecigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

14.11.24PR NewswirePrecigen Reports Third Quarter 2024 Financial Results and Business Updates

12.11.24PR NewswirePrecigen to Participate in the Stifel 2024 Healthcare Conference

16.09.24PR NewswirePrecigen to Participate in the 2024 Cantor Global Healthcare Conference

14.08.24PR NewswirePrecigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

09.08.24PR NewswirePrecigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

06.08.24PR NewswirePrecigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

23.07.24PR NewswirePrecigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

03.06.24PR NewswirePrecigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

23.05.24PR NewswirePrecigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

14.05.24PR NewswirePrecigen Reports First Quarter 2024 Financial Results and Business Updates

Precigen News

Precigen News: auf dieser Seite finden Sie alle Precigen News und Nachrichten zur Precigen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Precigen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Precigen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.